Funder
National Institute of Nursing Research
Publisher
Springer Science and Business Media LLC
Reference61 articles.
1. Becasen JS, Denard CL, Mullins MM, Higa DH, Sipe TA. Estimating the prevalence of HIV and sexual behaviors among the US transgender population: a systematic review and meta-analysis, 2006–2017. Am J Public Health. 2019;109.
2. Bukowski LA, Chandler CJ, Creasy SL, Matthews DD, Friedman MR, Stall RD. Characterizing the HIV Care Continuum and Identifying Barriers and Facilitators to HIV Diagnosis and Viral Suppression Among Black Transgender Women in the United States. J Acquir Immune Defic Syndr. 1999. 2018;79:413–20.
3. Centers for Disease Control and Prevention. HIV infection, Risk, Prevention, and Testing Behaviors Among Transgender Women - National HIV Behavioral Surveillance, 7, Citites US. April, 2019–2020. HIV Surveillance Special Report 27. https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-special-report-number-27.pdf. Published 2021. Accessed May 3, 2024.
4. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4:151ra125.
5. Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 1999. 2014;66:340–8.